in Health care
Amubarvimab/romlusevimab reduces hospitalization and death by 79% in adults diagnosed with COVID-19: Study
As COVID-19 evolves, the development of safe and effective therapeutics is a high priority. Amubarvimab and romlusevimab are non-competing anti-SARS-CoV-2 monoclonal antibodies with an extended half-life that may be an effective and safe option for persons who are at high risk of clinical progression to severe COVID-19. A randomized controlled trial of more than 800 […] More
